(19)
(11)EP 0 205 098 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
22.03.1989 Bulletin 1989/12

(43)Date of publication A2:
17.12.1986 Bulletin 1986/51

(21)Application number: 86107631.3

(22)Date of filing:  05.06.1986
(51)International Patent Classification (IPC)4A61K 39/145
(84)Designated Contracting States:
AT BE CH DE FR GB IT LI NL SE

(30)Priority: 06.06.1985 JP 123341/85

(71)Applicants:
  • National Institute of Health
    Shinagawa-ku Tokyo (JP)
  • DAIICHI SEIYAKU CO., LTD.
    Chuo-ku Tokyo 103 (JP)
  • Juridical Foundation The Chemo-Sero-Therapeutic Research Institute
    Kumamoto-shi Kumamoto-ken (JP)

(72)Inventors:
  • Nerome, Kuniaki
    Meguro-ku Tokyo (JP)
  • Oya, Akira
    Meguro-ku Tokyo (JP)
  • Ohkuma, Kunio
    Kumamoto-shi Kumamoto-ken (JP)
  • Inoue, Atsuo
    Funabashi-shi Chiba-ken (JP)

(74)Representative: VOSSIUS & PARTNER 
Postfach 86 07 67
81634 München
81634 München (DE)


(56)References cited: : 
  
      


    (54)Influenza vaccine


    (57) This invention relates to a novel influenza vaccine comprising a complex of HANA antigen and an MDP derivative.
    The novel vaccine is prepared by mixing an influenza HANA antigen and at least one MDP derivative in a suitable medium; solubilizing the resulting mixture with a surface active agent capable of being removed by dialysis, the solubilization being conducted in the presence or absence of cholesterol, lecithin and dicetyl phosphate or a mixture thereof; and then removing the surface active agent therefrom by dialysis to obtain an influenza vaccine comprising artificial vesicle-like particles of a complex of HANA antigen and MDP derivative, where the MDP derivative forms a membrane of the particle (corresponding to the lipid membrane of natural influenza virus particle) on the surface of which there exists the HANA antigen being bonded to the MDP derivative so as to form the complex. Thus, said aritificial vesicle-like particle of the HANA antigen-MDP derivative complex has nearly the same particle size and shape as the natural influenza virus particle.
    The novel vaccine has an improved immunogenecity compared with the conventional vaccine.





    Search report